Clinical pharmacology of angiotensin II receptor blockers: valsartan

Abstract

Angiotensin II receptor blockers (ARBs), or sartans, are a group of pharmaceuticals that modulate the renin-angiotensin-aldosterone system (RAAS). They are more successful in blocking the effects of AT II compared to ACE inhibitors, and are characterized by higher tolerability. Large comparative studies with ARA II were completed lately, including studies on long-term efficacy and impact on prognosis. The obtained evidence base contributed to the expansion of indications for clinical use of sartans in the treatment of arterial hypertension (AH) and comorbid conditions. The action produced by ARBs is not age-dependent, not characterized by escape phenomenon in the context of long-term use; ARBs have implicit organ-protective and pleiotropic properties, and are metabolically neutral compared to other antihypertensive drugs. The available medications belonging to the ARB class have very specific pharmacological and pharmacokinetic properties that determine some of their clinical effects.

Keywords

• антагонисты рецепторов ат ii
• сартаны
• фармакокинетика
• метаболизм
• гипотензивная эффективность
• органопротективные эффекты
• нефропротекция
• нейропротекция
• angiotensin ii receptor blockers
• sartans
• pharmacokinetics
• metabolism
• antihypertensive effect
• organ-protective effects
• nephroprotection
• neuroprotection